A quantified licensing exposure is only protective if it reaches the price or the structure. Here is how buyers turn a cost to cure into a defensible purchase price adjustment the seller can engage with.
Pricing software exposure into the purchase price is the step that turns a quantified licensing risk into protection. A cost to cure that sits in a diligence report but never reaches the price or the structure protects nobody. The buyer still pays full enterprise value and still absorbs the exposure when it surfaces after close. Pricing it in moves that cost from the buyer's post close surprise to a negotiated term the seller engages with, whether through a lower price, an escrow, or a specific indemnity. This page sets out how to do it defensibly.
The purpose of quantifying a software exposure is to act on it, and the most direct action is to reflect it in what the buyer pays. An exposure that is identified but not priced in is simply risk the buyer has chosen to accept, usually without realising it. When the publisher audit arrives after close, that buyer pays the cure cost on top of the full price already paid, with no recourse to the seller. The exposure has not gone away by being noted; it has only changed hands quietly.
Pricing it in changes the conversation from the buyer's problem to a shared one. A seller who wants the deal to close has reason to engage with a quantified, evidenced exposure, because the alternative is a buyer who walks or discounts unilaterally. The mechanism chosen depends on how certain and how large the exposure is, but the principle is constant: the cost belongs in the deal economics, not in the buyer's first year of ownership.
There is a mechanism for every shape of exposure. A quantified and likely exposure suits a straight purchase price reduction, lowering the enterprise value paid. An exposure that is probable but uncertain in size suits an escrow or holdback, where funds are withheld pending the outcome, as set out in escrow and holdbacks for licensing risk. An identified but contingent exposure suits a specific indemnity, where the seller covers a defined claim if it materialises.
The choice is not only financial, it is about who is best placed to bear the risk and the uncertainty. Where the buyer can quantify the cure cost confidently, a price reduction is cleanest. Where the size depends on how a publisher will assess the position, an escrow keeps funds available without forcing a number neither side can yet agree. The allocation of these mechanisms into the agreement is covered in negotiating software risk allocation in the SPA. The table summarises the fit.
| Mechanism | When it fits | Effect |
|---|---|---|
| Purchase price reduction | Exposure is quantified and likely | Lowers enterprise value paid |
| Escrow or holdback | Exposure is probable but uncertain in size | Funds withheld pending outcome |
| Specific indemnity | Exposure is identified but contingent | Seller covers a defined claim |
| Working capital adjustment | Exposure affects the closing balance | Reflected in completion accounts |
| Walk or renegotiate | Exposure is large and seller will not engage | Protects against overpaying |
A seller can dismiss a round number, but cannot easily dismiss an independent, evidenced cost to cure that shows the entitlement gap and what it costs to close. This is why the quantification has to come first and has to be defensible. The method is set out in quantifying cost to cure for the deal model, and the quality of that number determines whether the price conversation succeeds. A vague concern invites a flat denial; a reconciled exposure invites a negotiation.
The number is built by reconciling entitlement against deployment, testing the change of control and indirect access positions, and costing the path to a compliant estate. Because the work is independent and buyer aligned, paid only by the acquirer, the resulting figure carries weight at the negotiating table. It is the difference between asking the seller to take the buyer's word and showing the seller the evidence, the core of software spend diligence.
Pricing exposure in assumes the deal still makes sense once it is reflected. Sometimes it does not. Where the exposure is large enough to break the investment case and the seller will not engage on price or structure, the disciplined move is to renegotiate hard or walk away rather than absorb a risk that swamps the return. The scale of what can be at stake is shown by public disputes: SAP pursued AB InBev for a reported 600 million dollars and Diageo for a reported 60 million over disputed and inherited licensing, as of June 2026.
Most deals do not reach that point, because most exposures can be priced in once they are quantified. But the willingness to walk is what gives the buyer leverage to price in at all. A seller who knows the buyer will accept any exposure has no reason to share the cost; a seller who knows the buyer has a defensible number and the discipline to act on it has every reason to engage. This is commercial and licensing advisory, not legal advice, so engage your own counsel on the interpretation of any clause.
Pricing software exposure into the purchase price is one step in software in deal valuation, following the quantification of the cure cost and feeding the allocation of risk in the agreement. Engage your own counsel for legal interpretation of any contract, clause, or claim.
Tell us where the deal stands. We respond within one business day with a scoped, buyer side engagement that protects the value you underwrote.
Book a confidential call